BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190309
DTEND;VALUE=DATE:20190411
DTSTAMP:20260730T070832
CREATED:20190309T131805Z
LAST-MODIFIED:20190309T133035Z
UID:21106-1552089600-1554940799@ces.b2sg.org
SUMMARY:In Vivo Pharmacology Scientist (non-PhD)
DESCRIPTION:We seek an accomplished Scientist level oncologist/immunologist to join the in vivo pharmacology group within the Oncology Research Unit (ORU) of Pfizer’s Worldwide Research & Development (WRD) division in La Jolla\, California. The successful candidate will join a dynamic team of scientists in the Oncology In Vivo Pharmacology Group\, playing a leading role in the characterization of models of cancer and evaluating new drug candidates. \nParticipate in pre-clinical drug discovery and development projects with a focus on targeted therapeutics\, epigenetics and the tumor microenvironment. Characterize and develop small molecules in close collaboration with partner lines as an integral member of drug discovery teams. Evaluate anti-tumor effects in combination with biologics. Employ and develop new cutting-edge in vivo mouse and human cancer models. Provide technical and scientific expertise in in vivo pharmacology to the tumor cell biology department to enable target identification\, validation\, prioritization and efficient drug discovery of small molecules. \nThe candidate must have a strong background in hands-on laboratory based experimentation.   Experience with scRNA sequencing technologies (10X Genomics) is required. Knowledge in multi-parameter flow cytometry analysis of tumor infiltrating immune cells (Fortessa-X20\, Cytobank\, FlowJo\, FACS\, MACS) is desired. Ideal applicants will have excellent communication and organizational skills\, critical problem-solving abilities\, and a commitment to excellence. \nROLE RESPONSIBILITIES  \n\nExecute and analyze cells within the tumor microenvironment by multi-parameter flow cytometric and RNAseq studies.\nCharacterize new in vivo mouse models\, including syngeneic tumor and genetically engineered mouse (GEM) models\, to study biologic mechanisms and support exploration of novel therapies.\nConduct in vivo studies to evaluate and establish efficacy\, PK/PD relationship\, combination strategy\, biomarker identification and analysis.\nInterpretation\, presentation and documentation of experiments.\nPresentation of results within a multidisciplinary team environment.\n\nBASIC QUALIFICATIONS  \n\nBS/MS in Cancer Biology\, Immunology or equivalent experience in a related discipline.\n> 6 years of laboratory work experience in academia or industry\nHands on laboratory skills. In vivo skills (IV\, PO dosing)\, blood/tissue collection is a plus.\nAbility to follow novel scientific or technological developments\, and to implement them in the laboratory.\nExcellent written and oral communication and presentation skills in English.\nStrong ability to multi-task and work productively in a fast-paced\, highly collaborative\, and diverse team environment. Capability to contribute to a vivid and challenging intellectual environment.\n\nPREFERRED QUALIFICATIONS \n\nExpertise in multi-parameter flow cytometry analysis of tumor infiltrating immune cells (Fortessa-X20\, Cytobank\, FlowJo\, FACS\, MACS) or scRNA sequencing technologies (10X Genomics) preferred\nExperience with animal models of human cancers preferred.
URL:https://ces.b2sg.org/event/9mar19/
LOCATION:Pfizer – La Jolla\, CA\, 10350 N Torrey Pines Rd\, La Jolla\, CA\, 92037\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/pfizer_new_logo.jpg
END:VEVENT
END:VCALENDAR